UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050587
Receipt number R000057531
Scientific Title The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer
Date of disclosure of the study information 2023/03/24
Last modified on 2023/03/14 12:22:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer

Acronym

The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer

Scientific Title

The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer

Scientific Title:Acronym

The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer

Region

Japan


Condition

Condition

Biliary tract cancer

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To identify intratumoral/bile microbiome that is related to progression-free survival/prognosis in palliative chemotherapy for biliary tract cancer.

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Relationship between intratumoral microbiome and progression-free survival in patients with biliary tract cancer

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) patients who undergo palliative chemotherapy
(2) patients who underwent ERCP rerated procedure
(3) patients who were diagnosed of biliary tract cancer by pathological analyses

Key exclusion criteria

(1) combination with other malignancies
(2) cholangitis at sample collection
(3) unclear about history of antibiotic use within 3 months at sample collection
(4) unsuitable for inclusion at the discretion of the physician

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Masaki
Middle name
Last name Kuwatani

Organization

Hokkaido University Hospital

Division name

Department of Gastroenterology and Hepatology

Zip code

060-8648

Address

North 14, West 5, Kita-ku, Sapporo, Japan

TEL

011-716-1161

Email

mkuwatan@med.hokudai.ac.jp


Public contact

Name of contact person

1st name Ryo
Middle name
Last name Sugiura

Organization

Hokkaido University Faculty of Medicine and Graduate School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

060-8638

Address

North 15, West 7, Kita-ku, Sapporo

TEL

011-716-1161

Homepage URL


Email

rsugiura-hok@umin.ac.jp


Sponsor or person

Institute

Hokkaido University Hospital

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Review Board for Life Science and Medical Research, Hokkaido University Hospital

Address

North 14, West 5, Kita-ku, Sapporo

Tel

011-706-7636

Email

crjimu@huhp.hokudai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2023 Year 02 Month 21 Day

Date of IRB

2023 Year 02 Month 21 Day

Anticipated trial start date

2023 Year 02 Month 21 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Single-center prospective observational cohort study


Management information

Registered date

2023 Year 03 Month 15 Day

Last modified on

2023 Year 03 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057531


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name